This observational study is conducted in Europe. The trial aims to observe the incidence of serious adverse drug reactions in children and adolescents with type 1 diabetes during Levemir® treatment.
Study Type
OBSERVATIONAL
Enrollment
159
No extra intervention, only normal clinical practise for treatment of type 1 diabetes
Novo Nordisk Investigational Site
Lund, Sweden
Incidence of serious adverse drug reactions, including major hypoglycaemic events
Time frame: after 6 month treatment
Number of all hypoglycaemic events
Time frame: after 6 month treatment
Number of adverse drug reactions
Time frame: after 6 month treatment
BMI changes
Time frame: after 6 month treatment
HbA1c
Time frame: after 6 month treatment
Variability in FPG (Fasting Plasma Glucose)
Time frame: after 6 month treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.